This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2402309 (2024)
Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400201 (2024)
Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0959 (2024)
Related article
Brandts, J. & Ray, K. K. et al. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat. Rev. Cardiol. 20, 600–616 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huynh, K. RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia. Nat Rev Cardiol (2024). https://doi.org/10.1038/s41569-024-01034-w
Published:
DOI: https://doi.org/10.1038/s41569-024-01034-w